Clinical breast cancerForce J, Howie LJ, Abbott SE, Bentley R, Marcom PK, Kimmick G, et al. Early stage HER2-positive breast cancers not achieving a pCR From neoadjuvant trastuzumab- or pertuzumab-based regimens have an immunosuppressive phenotype. Clin Breast Cancer. 2018;18(5):410-7....
Matthew,James,Ellis - 《J Natl Cancer Inst》 被引量: 3发表: 2014年 Early Stage HER2 Positive Breast Cancers Not Achieving A pCR From Neoadjuvant Trastuzumab Or Pertuzumab Based Regimens Have An Immunosuppressive Phenotype Early stage HER2-positive breast cancers not achieving a pCR From neoadjuvant...
September 14, 2021 Author(s): OncLive Staff In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer....
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized disease has been chemotherapy and 1 year of adjuvant HER2-targeted therapy, typically with the anti-HER2 antibody trastuzumab. Despite the ...
Dr Ian Krop will talk about a case of a patient with early-stage HER2-positive breast cancer.Ian Krop, MD, PhD: Thanks, Hope. I think I have a case that’s interesting, both because it presents some good medical oncology discussion points but also because it presents some good pathology...
Swain, MD, associate dean for research development and professor of medicine at the Georgetown University Medical Cancer, outlines the treatment landscape of early-stage HER2-positive (HER2+) breast cancer and discusses how recent data will impact treatment paradigms. Targeted Oncology™: Ple...
with metastaticHER2-positive breast cancer-aform of breast cancer that exhibits amplification of the gene encoding [...] chinese.eurekalert.org chinese.eurekalert.org 转移性人类上皮生长因子受体2(HER2)阳性乳腺癌——这是一种表现为人类上皮生长因子受体2(HER2)编码的基因扩增的乳腺癌——的病人常常出现肿...
De-intensif i cation of therapy for early-stage HER2-positive breast cancerDe-intensif i cation of breast cancer treatment is a laudable goal. Fewer aggressive breast and axillary surgeries are now needed to achieve excellent out-comes, and genomic assays can help to identify patients in whom ad...
, MD, PhD:So, let’s move on to HER2-positive breast cancer. And I think that the questions that have been asked in the last couple of months to years with this is, what do we do with the triple-positive, the HER2-positive, and ER-positive group of patients in the early stage?
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.